Skip to main content
SpringerLink
Log in

Hepatitis B Virus Drug Resistance

  • Chapter
  • First Online:
Antimicrobial Drug Resistance

Abstract

The prevention and management of antiviral drug resistance remain central aspects of treatment strategies against infection with the hepatitis B virus (HBV). Whilst current therapeutic options for the de novo treatment of chronic hepatitis B (CHB) carry a low risk of selecting for drug resistance, indefinite treatment is commonly required. Importantly, many patients have accumulated HBV drug resistance and cross-resistance through previous, less efficacious therapy and have limited treatment options. Large numbers also continue to be at risk of drug resistance due to limited access to effective antiviral compounds in middle- and low-income settings.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Martin P, Lau DT, Nguyen MH, Janssen HL, Dieterich DT, Peters MG, Jacobson IM. A Treatment algorithm for the management of chronic hepatitis B virus Infection in the United States: 2015 update. Clin Gastroenterol Hepatol. 2015;13(12):2071–87.e16.

    Google Scholar 

  2. Buti M. HBeAg-positive chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogs? Liver Int. 2014;34 Suppl 1:108–11.

    Article  CAS  PubMed  Google Scholar 

  3. Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 2013;12:447–64.

    Article  CAS  PubMed  Google Scholar 

  4. Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut. 2012;61 Suppl 1:i18–24.

    Article  CAS  PubMed  Google Scholar 

  5. Zoulim F, Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med. 2015;1:5(4).

    Google Scholar 

  6. Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res. 2015;121:69–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Wang XY, Chen HS. Emerging antivirals for the treatment of hepatitis B. World J Gastroenterol. 2014;20:7707–17.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology. 2007;132:1574–85.

    Article  CAS  PubMed  Google Scholar 

  9. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res. 2008;134:235–49.

    Article  CAS  PubMed  Google Scholar 

  10. Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology. 1989;170:595–7.

    Article  CAS  PubMed  Google Scholar 

  11. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A. 1996;93:4398–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Aoudjane S, Chaponda M, del Castillo AAG, O’Connor J, Noguera M, Beloukas A, Hopkins M, Khoo S, van Oosterhout JJ, Geretti AM. Hepatitis B virus sub-genotype A1 infection Is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi. Clin Infect Dis. 2014;59:1618–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254–65.

    Article  CAS  PubMed  Google Scholar 

  14. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol. 2006;44:593–606.

    Article  CAS  PubMed  Google Scholar 

  15. Geretti AM, Patel M, Sarfo FS, Chadwick D, Verheyen J, Fraune M, Garcia A, Phillips RO. Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana. J Clin Microbiol. 2010;48:3223–30.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lacombe K, Boyd A, Lavocat F, Pichoud C, Gozlan J, Miailhes P, Lascoux-Combe C, Vernet G, Girard PM, Zoulim F. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. Hepatology. 2013;58:912–22.

    Article  CAS  PubMed  Google Scholar 

  17. Coffin CS, Mulrooney-Cousins PM, Peters MG, van Marle G, Roberts JP, Michalak TI, Terrault NA. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J Viral Hepat. 2011;18:415–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972–84.

    Article  CAS  PubMed  Google Scholar 

  19. Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12:341–53.

    Article  PubMed  Google Scholar 

  20. Wong DK, Seto WK, Fung J, Ip P, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol. 2013;11:1004–10.

    Article  CAS  PubMed  Google Scholar 

  21. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593–608.

    Article  CAS  PubMed  Google Scholar 

  22. Pan WL, Hu JL, Fang Y, Luo Q, Xu G, Xu L, Jing ZH, Shan XF, Zhu YL, Huang AL. Allele-specific polymerase chain reaction for detection of a mutation in the relax circular DNA and the covalently closed circular DNA of hepatitis B virus. J Virol Methods. 2013;194:277–9.

    Article  CAS  PubMed  Google Scholar 

  23. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology. 2001;33:751–7.

    Article  CAS  PubMed  Google Scholar 

  24. Kao JH. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int. 2014;34 Suppl 1:112–9.

    Article  CAS  PubMed  Google Scholar 

  25. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008;8:559–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Huser N, Durantel D, Liang TJ, Munk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343:1221–8.

    Article  CAS  PubMed  Google Scholar 

  27. Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, Panno AM, Bernardi M, Brander C, Bihl F, Andreone P, Maini MK. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol. 2013;58:225–33.

    Article  CAS  PubMed  Google Scholar 

  28. Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol. 2013;58:205–9.

    Article  PubMed  Google Scholar 

  29. Lin CL, Kao JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015;5:a021436.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Tseng TC, Liu CJ, Kao JH. Implications of hepatitis B virus genomic variations on treatment outcomes. Curr Pharmacogenomics Person Med. 2010;8:280–8.

    Article  CAS  Google Scholar 

  31. De Clercq E. Current treatment of hepatitis B virus infections. Rev Med Virol. 2015;25(6):354–65.

    Article  PubMed  CAS  Google Scholar 

  32. De Clercq E. Strategies in the design of antiviral drugs. Nat Rev Drug Discov. 2002;1:13–25.

    Article  PubMed  CAS  Google Scholar 

  33. Wilkins E, Nelson M, Agarwal K, Awoyemi D, Barnes E, Bhagani S, Brook G, Brown A, Castelino S, Cooke G, Fisher M, Geretti AM, James R, Kulasegaram R, Leen C, Mutimer D, Orkin C, Page E, Palfreeman A, Papineni P, Rodger A, Tong CY. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med. 2013;14 Suppl 4:1–71.

    CAS  Google Scholar 

  34. Domaoal RA, McMahon M, Thio CL, Bailey CM, Tirado-Rives J, Obikhod A, Detorio M, Rapp KL, Siliciano RF, Schinazi RF, Anderson KS. Pre-steady-state kinetic studies establish entecavir 5′-triphosphate as a substrate for HIV-1 reverse transcriptase. J Biol Chem. 2008;283:5452–9.

    Article  CAS  PubMed  Google Scholar 

  35. Menendez-Arias L, Alvarez M, Pacheco B. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Curr Opin Virol. 2014;8:1–9.

    Article  CAS  PubMed  Google Scholar 

  36. Bozdayi AM, Uzunalimoglu O, Turkyilmaz AR, Aslan N, Sezgin O, Sahin T, Bozdayi G, Cinar K, Pai SB, Pai R, Bozkaya H, Karayalcin S, Yurdaydin C, Schinazi RF. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat. 2003;10:256–65.

    Article  CAS  PubMed  Google Scholar 

  37. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol. 2001;75:4771–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol. 2003;77:11833–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Jones SA, Murakami E, Delaney W, Furman P, Hu J. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine. Antimicrob Agents Chemother. 2013;57:4181–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kwon SY, Park YK, Ahn SH, Cho ES, Choe WH, Lee CH, Kim BK, Ko SY, Choi HS, Park ES, Shin GC, Kim KH. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol. 2010;84:4494–503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687–96.

    Article  CAS  PubMed  Google Scholar 

  42. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129:528–36.

    Article  CAS  PubMed  Google Scholar 

  43. Lim SG, Krastev Z, Ng TM, Mechkov G, Kotzev IA, Chan S, Mondou E, Snow A, Sorbel J, Rousseau F. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother. 2006;50:1642–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, Lee SS, Chan S, Shiffman ML, Washington MK, Rigney A, Anderson J, Mondou E, Snow A, Sorbel J, Guan R, Rousseau F. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006;166:49–56.

    Article  CAS  PubMed  Google Scholar 

  45. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008;2:147–51.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Nakanishi H, Kurosaki M, Asahina Y, Onuki Y, Ueda K, Nishimura Y, Tsuchiya K, Kitamura T, Uchihara M, Miyake S, Enomoto N, Izumi N. Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B. Intervirology. 2005;48:381–8.

    Article  CAS  PubMed  Google Scholar 

  47. Pai SB, Bozdayi AM, Pai RB, Beker T, Sarioglu M, Turkyilmaz AR, Grier J, Yurdaydin C, Schinazi RF. Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy. Antimicrob Agents Chemother. 2005;49:2618–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Seifer M, Patty A, Serra I, Li B, Standring DN. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res. 2009;81:147–55.

    Article  CAS  PubMed  Google Scholar 

  49. Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology. 2014;59:1283–92.

    Article  CAS  PubMed  Google Scholar 

  50. Yuen L, Bartholomeusz A, Ayres A, Littlejohn M, Locarnini S. Multidrug resistance and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatology. 2008;2(2):147–51.

    Article  Google Scholar 

  51. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther. 2004;9:353–63.

    CAS  PubMed  Google Scholar 

  52. Karatayli E, Karayalcin S, Karaaslan H, Kayhan H, Turkyilmaz AR, Sahin F, Yurdaydin C, Bozdayi AM. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther. 2007;12(5):761–8.

    CAS  PubMed  Google Scholar 

  53. Lacombe K, Ollivet A, Gozlan J, Durantel S, Tran N, Girard PM, Zoulim F. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS. 2006;20:2229–31.

    Article  CAS  PubMed  Google Scholar 

  54. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, Zoulim F. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 2008;48:747–55.

    Article  CAS  PubMed  Google Scholar 

  55. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology. 2008;48:88–98.

    Article  CAS  PubMed  Google Scholar 

  56. Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H, Abe H, Maekawa T, Tateno C, Yoshizato K, Suzuki F, Kumada H, Chayama K. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother. 2006;50:3867–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology. 2000;31:1318–26.

    Article  CAS  PubMed  Google Scholar 

  58. Liu Y, Xu Z, Wang Y, Li X, Liu L, Chen L, Xin S, Xu D. rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus. PLoS One. 2014;9:e89015.

    Google Scholar 

  59. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology. 1998;27:1670–7.

    Article  CAS  PubMed  Google Scholar 

  60. Chong Y, Stuyver L, Otto MJ, Schinazi RF, Chu CK. Mechanism of antiviral activities of 3′-substituted L-nucleosides against 3TC-resistant HBV polymerase: a molecular modelling approach. Antivir Chem Chemother. 2003;14:309–19.

    Article  CAS  PubMed  Google Scholar 

  61. Lee K, Chu CK. Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents. Antimicrob Agents Chemother. 2001;45:138–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Hong YB, Choi Y, Jung G. Increased DNA polymerase fidelity of the lamivudine resistant variants of human hepatitis B virus DNA polymerase. J Biochem Mol Biol. 2004;37:167–76.

    CAS  PubMed  Google Scholar 

  63. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–88.

    Article  CAS  PubMed  Google Scholar 

  64. Liaw YF, Gane E, Leung N, Zeuzem S, Wang YM, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu JQ, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen YG, Brown NA, Albanis E, Galil K, Naoumov NV. 2-Year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–95.

    Article  CAS  PubMed  Google Scholar 

  65. Chan HLY, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, Minuk GY, Jeffers L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007;147:745–54.

    Article  PubMed  Google Scholar 

  66. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan M, Chen C, Wu S, Chen Y, Xu J, Wang Q, Wei L, Chao G, Constance BF, Harb G, Brown NA, Jia J. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47:447–54.

    Article  CAS  PubMed  Google Scholar 

  67. Lui YY, Chan HL. A review of telbivudine for the management of chronic hepatitis B virus infection. Expert Opin Drug Metab Toxicol. 2008;4:1351–61.

    Article  CAS  PubMed  Google Scholar 

  68. Tsai MC, Yu HC, Hung CH, Lee CM, Chiu KW, Lin MT, Tseng PL, Chang KC, Yen YH, Chen CH, Hu TH. Comparing the efficacy and clinical outcome of telbivudine and entecavir naive patients with hepatitis B virus-related compensated cirrhosis. J Gastroenterol Hepatol. 2014;29:568–75.

    Article  CAS  PubMed  Google Scholar 

  69. Yuen MF, Lai CL. Telbivudine: an upcoming agent for chronic hepatitis B. Expert Rev Anti Infect Ther. 2005;3:489–94.

    Article  CAS  PubMed  Google Scholar 

  70. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.

    Article  CAS  PubMed  Google Scholar 

  71. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422–30.

    Article  CAS  PubMed  Google Scholar 

  72. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44:1656–65.

    Article  CAS  PubMed  Google Scholar 

  73. Gish RG, Lok AS, Chang TT, Lde Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133:1437–44.

    Article  CAS  PubMed  Google Scholar 

  74. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–20.

    Article  CAS  PubMed  Google Scholar 

  75. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503–14.

    Article  CAS  PubMed  Google Scholar 

  76. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, Zoulim F. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 2007;46:531–8.

    Article  CAS  PubMed  Google Scholar 

  77. Baldick CJ, Tenney DJ, Mazzucco CE, Eggers BJ, Rose RE, Pokornowski KA, Yu CF, Colonno RJ. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology. 2008;47:1473–82.

    Article  CAS  PubMed  Google Scholar 

  78. Hayashi S, Murakami S, Omagari K, Matsui T, Iio E, Isogawa M, Watanabe T, Karino Y, Tanaka Y. Characterization of novel entecavir resistance mutations. J Hepatol. 2015;63:546–53.

    Article  CAS  PubMed  Google Scholar 

  79. Reijnders JGP, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bommel F, Hansen BE, Wedemeyer H, Janssen HLA. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol. 2010;52:493–500.

    Article  CAS  PubMed  Google Scholar 

  80. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130:2039–49.

    Article  CAS  PubMed  Google Scholar 

  81. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother. 2004;48:3498–507.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. De Clercq E, Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov. 2005;4:928–40.

    Article  PubMed  CAS  Google Scholar 

  83. Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48:750–8.

    Article  CAS  PubMed  Google Scholar 

  84. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–55.

    Article  CAS  PubMed  Google Scholar 

  85. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003;125:292–7.

    Article  PubMed  Google Scholar 

  86. Qi X, Xiong S, Yang H, Miller M, Delaney WE. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007;12:355–62.

    CAS  PubMed  Google Scholar 

  87. Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, Helm M, Rockstroh JK, Willems WR, Will H, Gerlich WH. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006;354:1807–12.

    Article  CAS  PubMed  Google Scholar 

  88. Yadav V, Chu CK. Molecular mechanisms of adefovir sensitivity and resistance in HBV polymerase mutants: a molecular dynamics study. Bioorg Med Chem Lett. 2004;14:4313–7.

    Article  CAS  PubMed  Google Scholar 

  89. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Schall RA, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Subramanian GM, Gane E, Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60:1457–64.

    Article  CAS  PubMed  Google Scholar 

  90. Delaney WE, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50:2471–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59:434–42.

    Article  CAS  PubMed  Google Scholar 

  92. Marcellin P, Gane E, Buti M, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–75.

    Article  CAS  PubMed  Google Scholar 

  93. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology. 2011;53:763–73.

    Article  CAS  PubMed  Google Scholar 

  94. van Bommel F, Zollner B, Sarrazin C, Spengler U, Huppe D, Moller B, Feucht HH, Wiedenmann B, Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44:318–25.

    Article  PubMed  CAS  Google Scholar 

  95. van Hemert FJ, Berkhout B, Zaaijer HL. Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus. PLoS One. 2014;9:e106324.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  96. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology. 2009;49:1158–65.

    Article  CAS  PubMed  Google Scholar 

  97. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, Nunez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005;10:727–34.

    CAS  PubMed  Google Scholar 

  98. Zhu Y, Curtis M, Borroto-Esoda K. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations. Antivir Chem Chemother. 2011;22:13–22.

    Article  PubMed  CAS  Google Scholar 

  99. Qin B, Budeus B, Cao L, Wu C, Wang Y, Zhang X, Rayner S, Hoffmann D, Lu M, Chen X. The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. Antiviral Res. 2013;97:93–100.

    Article  CAS  PubMed  Google Scholar 

  100. Boyd A, Gozlan J, Maylin S, Delaugerre C, Peytavin G, Girard PM, Zoulim F, Lacombe K. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications. Hepatology. 2014;60:497–507.

    Article  CAS  PubMed  Google Scholar 

  101. Childs K, Joshi D, Byrne R, Bruce M, Carey I, Agarwal K, Taylor C. Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia. AIDS. 2013;27:1443–8.

    Article  CAS  PubMed  Google Scholar 

  102. Matthews GV, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, Sasadeusz J, Revill PA, Littlejohn M, Hoy JF, Finlayson R, Ruxrungtham K, Saulynas M, Locarnini S, Thio CL. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis. 2013;56:e87–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Corsa AC, Liu Y, Flaherty JF, Marcellin P, Miller M, Kitrinos KM. No detectable resistance to tenofovir disoproxil fumarate (TDF) in HBeAg + and HBeAg- patients with chronic hepatitis B (CHB) after eight years of treatment. 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, November 7–11, 2014. Hepatology. 2014;60(Suppl 1):1020A.

    Google Scholar 

  104. Baran B, Soyer OM, Ormeci AC, Gokturk S, Evirgen S, Bozbey HU, Akyuz F, Karaca C, Demir K, Besisik F, Onel D, Gulluoglu M, Badur S, Kaymakoglu S. Efficacy of tenofovir in patients with lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2013;57:1790–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison JG, Husa P, Gane E. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146:980–8.

    Article  CAS  PubMed  Google Scholar 

  106. Stockdale AJ, Phillips RO, Beloukas A, Appiah LT, Chadwick D, Bhagani S, Bonnett L, Sarfo FS, Dusheiko G, Geretti AM. Liver fibrosis by transient elastography and virologic outcomes after introduction of tenofovir in lamivudine-experienced adults with HIV and Hepatitis B virus coinfection in Ghana. Clin Infect Dis. 2015;61:883–91.

    Article  CAS  PubMed  Google Scholar 

  107. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 2011;60:247–54.

    Article  CAS  PubMed  Google Scholar 

  108. Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. World J Gastroenterol. 2015;21:2746–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Svicher V, Cento V, Salpini R, Mercurio F, Fraune M, Beggel B, Han Y, Gori C, Wittkop L, Bertoli A, Micheli V, Gubertini G, Longo R, Romano S, Visca M, Gallinaro V, Marino N, Mazzotta F, De Sanctis GM, Fleury H, Trimoulet P, Angelico M, Cappiello G, Zhang XX, Verheyen J, Ceccherini-Silberstein F, Perno CF. Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis. 2011;43:975–83.

    Article  CAS  PubMed  Google Scholar 

  110. Zaaijer HL, Takkenberg RB, Weegink CJ, Rebers SP, Menting S, Reesink HW, Schinkel J, Molenkamp R. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir. J Med Virol. 2009;81:413–6.

    Article  CAS  PubMed  Google Scholar 

  111. EASL—European Association for the Study of Liver. Practice guidelines. 2012. http://www.easl.eu/research/our-contributions/clinical-practice-guidelines. Accessed 20 Aug 2015.

  112. Lazarevic I. Clinical implications of hepatitis B virus mutations: recent advances. World J Gastroenterol. 2014;20:7653–64.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  113. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother. 2001;12 Suppl 1:67–71.

    CAS  PubMed  Google Scholar 

  114. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–22.

    Article  CAS  PubMed  Google Scholar 

  115. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lik SG, Goodman Z, Ma J, Brosgart CL, Eorroto-Esoda K, Arterburn S, Chuck SL. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–51.

    Article  CAS  PubMed  Google Scholar 

  116. Lee HW, Kwon JC, Oh IS, Chang HY, Cha YJ, Choi IS, Kim HJ. Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response. Antimicrob Agents Chemother. 2015;9:5348–56.

    Article  CAS  Google Scholar 

  117. Ijaz S, Arnold C, Dervisevic S, Mechurova J, Tatman N, Tedder RS, Naoumov NV. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J Med Virol. 2008;80:1160–70.

    Article  CAS  PubMed  Google Scholar 

  118. Kurashige N, Hiramatsu N, Ohkawa K, Yakushijin T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Oshita M, Mita E, Hagiwara H, Nagase T, Yoshihara H, Hayashi E, Imai Y, Kato M, Kashihara T, Hayashi N. Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol. 2009;44:601–7.

    Article  CAS  PubMed  Google Scholar 

  119. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, Brosgart CL, Woessner MA, Scott SA, Gray DF, Gardner SD. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol. 2008;48:728–35.

    Article  CAS  PubMed  Google Scholar 

  120. Vassiliadis TG, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N, Mpoumponaris A, Gkisakis D, Theodoropoulos K, Panderi A, Katsinelos P, Eugenidis N. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. J Gastroenterol Hepatol. 2010;25:54–60.

    Article  CAS  PubMed  Google Scholar 

  121. Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol. 2011;26 Suppl 1:138–43.

    Article  PubMed  Google Scholar 

  122. Gomes-Gouvea MS, Ferreira AC, Teixeira R, Andrade JR, Ferreira AS, Barros LM, Rezende RE, Nastri AC, Leite AG, Piccoli LZ, Galvan J, Conde SR, Soares MC, Kliemann DA, Bertolini DA, Kunyoshi AS, Lyra AC, Oikawa MK, de Araujo LV, Carrilho FJ, Mendes-Correa MC, Pinho JR. HBV carrying drug-resistance mutations in chronically infected treatment-naive patients. Antivir Ther. 2015;20:387–95.

    Article  CAS  PubMed  Google Scholar 

  123. Vutien P, Trinh HN, Garcia RT, Nguyen HA, Levitt BS, Nguyen K, da Silveira E, Daugherty T, Ahmed A, Garcia G, Lutchman GA, Nguyen MH. Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients. Clin Gastroenterol Hepatol. 2014;12:1363–70.

    Article  CAS  PubMed  Google Scholar 

  124. Bayliss J, Nguyen T, Lesmana CRA, Bowden S, Revill P. Advances in the molecular diagnosis of hepatitis B infection: providing insight into the next generation of disease. Semin Liver Dis. 2013;33:113–21.

    Article  CAS  PubMed  Google Scholar 

  125. Geretti AM, Paredes R, Kozal MJ. Transmission of HIV drug resistance: lessons from sensitive screening assays. Curr Opin Infect Dis. 2015;28:23–30.

    Article  CAS  PubMed  Google Scholar 

  126. Beloukas A, King S, Childs K, Papadimitropoulos A, Hopkins M, Atkins M, Agarwal K, Nelson M, Geretti A. Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus (HCV) genotype 1a strains in the United Kingdom. Clin Microbiol Infect. 2015;21(11):1033–9.

    Article  CAS  PubMed  Google Scholar 

  127. Gianella S, Delport W, Pacold ME, Young JA, Choi JY, Little SJ, Richman DD, Kosakovsky Pond SL, Smith DM. Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol. 2011;85:8359–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis. 2006;26:171–80.

    Article  CAS  PubMed  Google Scholar 

  129. Ntziora F, Paraskevis D, Haida C, Manesis E, Papatheodoridis G, Manolakopoulos S, Elefsiniotis I, Karamitros T, Vassilakis A, Hatzakis A. Ultrasensitive amplification refractory mutation system real-time PCR (ARMS RT-PCR) assay for detection of minority hepatitis B virus-resistant strains in the era of personalized medicine. J Clin Microbiol. 2013;51:2893–900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis. 2007;11:797–816.

    Article  PubMed  Google Scholar 

  131. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98–107.

    Article  CAS  PubMed  Google Scholar 

  132. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57:399–408.

    Article  CAS  PubMed  Google Scholar 

  133. Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, Lai CL, Yuen MF. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol. 2013;59:709–16.

    Article  CAS  PubMed  Google Scholar 

  134. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology. 2008;134:405–15.

    Article  PubMed  Google Scholar 

  135. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132–43.

    Article  CAS  PubMed  Google Scholar 

  136. Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol. 2012;57:508–14.

    Article  CAS  PubMed  Google Scholar 

  137. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106:1264–71.

    Article  CAS  PubMed  Google Scholar 

  138. Yang YJ, Shim JH, Kim KM, Lim YS, Lee HC. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology. 2014;59:1303–10.

    Article  CAS  PubMed  Google Scholar 

  139. Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, Petersen J, Hofmann WP, Buti M, Santantonio T, van Bömmel F, Pradat P, Oo Y, Luetgehetmann M, Berg T, Hansen BE, Wedemeyer H, Janssen HL. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology. 2011;54:443–51.

    Article  CAS  PubMed  Google Scholar 

  140. Ha NB, Ha NB, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH. Response to higher dose of entecavir 1.0 mg daily in patients with partial response to entecavir 0.5 mg daily. J Clin Gastroenterol. 2013;47:461–5.

    Article  PubMed  Google Scholar 

  141. Lu L, Yip B, Trinh H, Pan CQ, Han SH, Wong CC, Li J, Chan S, Krishnan G, Wong CC, Nguyen MH. Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir. J Viral Hepat. 2015;22:675–81.

    Article  CAS  PubMed  Google Scholar 

  142. Ratcliffe L, Beadsworth MB, Pennell A, Phillips M, Vilar FJ. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS. 2011;25:1051–6.

    Article  CAS  PubMed  Google Scholar 

  143. AASLD—American Association for the Study of Liver Disease. Practice guidelines. 2009. http://www.aasld.org/publications/practice-guidelines-0. Accessed 30 Aug 2015.

  144. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J Viral Hepat. 2012;19:377–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Ke W, Liu L, Zhang C, Ye X, Gao Y, Zhou S, Yang Y. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One. 2014;9:e98865.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  146. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013;58:505–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, Gaggar A, Subramanian GM, McHutchison JG, Lau G, Lee S, Gane EJ. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 2014;146:1240–8.

    Article  CAS  PubMed  Google Scholar 

  148. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology. 2012;143:619–28.

    Article  CAS  PubMed  Google Scholar 

  149. Lui YY, Tsoi KK, Wong VW, Kao JH, Hou JL, Teo EK, Mohamed R, Piratvisuth T, Han KH, Mihm U, Wong GL, Chan HL. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir Ther. 2010;15:145–55.

    Article  CAS  PubMed  Google Scholar 

  150. Soriano V, McMahon B. Strategic use of lamivudine in the management of chronic hepatitis B. Antiviral Res. 2013;100:435–8.

    Article  CAS  PubMed  Google Scholar 

  151. Hermans L, Svicher V, Diepstraten Pas S, Salpini R, Alvarez M, Ben Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar M, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Weis N, Yalcinkaya T, Zidovec Lepej S, Perno C, Boucher C, Wensing AMJ. Combined analysis of the prevalence of drug-resistant hepatitis B virus in antiviral therapy-experienced patients in Europe. J Infect Dis. 2016;213(1):39–48.

    Google Scholar 

  152. Stockdale AJ, Geretti AM. Chronic hepatitis B infection in sub-Saharan Africa: a grave challenge and a great hope. Trans R Soc Trop Med Hyg. 2015;109:421–2.

    PubMed  Google Scholar 

  153. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, Rizzetto M, Craxi A. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40:883–91.

    Article  PubMed  Google Scholar 

  154. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2000;32:847–51.

    Article  CAS  PubMed  Google Scholar 

  155. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 1999;30:567–72.

    Article  CAS  PubMed  Google Scholar 

  156. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology. 2002;36:219–26.

    Article  PubMed  Google Scholar 

  157. Rizzetto M, Tassopoulos NC, Goldin RD, Esteban R, Santantonio T, Heathcote EJ, Lagget M, Taak NK, Woessner MA, Gardner SD. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2005;42:173–9.

    Article  CAS  PubMed  Google Scholar 

  158. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–31.

    Article  CAS  PubMed  Google Scholar 

  159. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 2006;26:162–70.

    Article  CAS  PubMed  Google Scholar 

  160. Van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. Long-term efficacy of tenofovir monotherapy for hepatitis B virus monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51:73–80.

    Article  PubMed  Google Scholar 

  161. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol. 2008;48:391–8.

    Article  CAS  PubMed  Google Scholar 

  162. Nguyen NH, Trinh HN, Nguyen TT, Do ST, Tran P, Nguyen HA, Nguyen KK, Garcia RT, Lutchman GA, Nguyen MH. Safety and efficacy of entecavir in adefovir-experienced patients. J Gastroenterol Hepatol. 2015;30:43–50.

    Article  CAS  PubMed  Google Scholar 

  163. Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ, Cho Y, Cho EJ, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother. 2014;58:6710–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  164. Lim YS, Yoo BC, Byun KS, Kwon SY, Kim YJ, An J, Lee HC, Lee YS. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2016;65(6):1042–51.

    Article  PubMed  Google Scholar 

  165. Lim YS, Byun KS, Yoo BC, Kwon SY, Kim YJ, An J, Lee HC, Lee YS. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut. 2016;65(5):852–60.

    Article  CAS  PubMed  Google Scholar 

  166. Yuen MF, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Lai CL, Han KH. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. J Hepatol. 2015;62:526–32.

    Article  CAS  PubMed  Google Scholar 

  167. Takamatsu Y, Tanaka Y, Kohgo S, Murakami S, Singh K, Das D, Venzon DJ, Amano M, Kuwata N, Aoki M, Delino NS, Hayashi S, Takahashi S, Sukenaga Y, Haraguchi K, Sarafianos SG, Maeda K, Mitsuya H. 4′-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus. Hepatology. 2015;62(4):1024–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Matthews PC, Geretti AM, Goulder PJ, Klenerman P. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol. 2014;61:20–33.

    Article  PubMed  Google Scholar 

  169. WHO—World Health Organisation. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015. http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/. Accessed 30 Aug 2015.

Download references

Author information

Authors and Affiliations

  1. Institute of Infection and Global Health, University of Liverpool, West Derby Street, Liverpool, L69 7BE, UK

    Apostolos Beloukas M.Sc., Ph.D.

  2. Professor of Virology and Infectious Diseases, Honorary Consultant in Infectious Diseases, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK

    Anna Maria Geretti M.D., Ph.D., FRCPath.

Authors
  1. Apostolos Beloukas M.Sc., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Maria Geretti M.D., Ph.D., FRCPath.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Maria Geretti M.D., Ph.D., FRCPath. .

Editor information

Editors and Affiliations

  1. Treiber Therapeutics, Cambridge, Massachusetts, USA

    Douglas L. Mayers

  2. Wayne State University School of Medicine, Detroit Medical Center, Detroit, Michigan, USA

    Jack D. Sobel

  3. Canada Research Chair in Antimicrobial Resistance, Centre de recherche en Infectiologie, University of Laval, Quebec City, Canada

    Marc Ouellette

  4. Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA

    Keith S. Kaye

  5. Infection Control and Prevention Unit of Infectious Diseases, Assaf Harofeh Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

    Dror Marchaim

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Beloukas, A., Geretti, A.M. (2017). Hepatitis B Virus Drug Resistance. In: Mayers, D., Sobel, J., Ouellette, M., Kaye, K., Marchaim, D. (eds) Antimicrobial Drug Resistance. Springer, Cham. https://doi.org/10.1007/978-3-319-47266-9_26

Download citation

Publish with us

Policies and ethics

Search

Navigation